Tracks how adults with schizophrenia feel about xanomeline and trospium treatment
Studies treatment preference and satisfaction in adults with schizophrenia taking xanomeline and trospium.
Plain-language title generated from the registry record
Registry title: Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Key facts
- Where
- Baltimore, Bel Air, Belle Mead, Belmont, Boston, Catonsville, El Paso, Evanston, Fort Mill, Grand Island, Kinston, Longview, Miami, New York, Omaha, Orange, Rose Hill, San Jose, South Dartmouth, and Westlake, United StatesSee the 20 sites
Where in United States
- The Johns Hopkins HospitalBaltimore, United StatesTaking people
- Bel AirBel Air, United StatesNo longer taking part
- Hackensack Meridian Health - Carrier ClinicBelle Mead, United StatesTaking people
- BelmontBelmont, United StatesNo longer taking part
- Boston Medical CenterBoston, United StatesTaking people
- CatonsvilleCatonsville, United StatesNo longer taking part
- Haracec Clinical ResearchEl Paso, United StatesTaking people
- Evanston HospitalEvanston, United StatesTaking people
- Continuum Health ProvidersFort Mill, United StatesTaking people
- Grand IslandGrand Island, United StatesNot yet recruiting
- New Dawn Psychiatric Services, PLLCKinston, United StatesTaking people
- C-Trilogy OutreachLongview, United StatesTaking people
- MiamiMiami, United StatesNot yet recruiting
- Radial - ManhattanNew York, United StatesTaking people
- Omaha Insomnia and Psychiatric ServicesOmaha, United StatesTaking people
- ATP Clinical Research - Costa MesaOrange, United StatesTaking people
- New Dimension GroupRose Hill, United StatesTaking people
- Lumos Clinical Research CenterSan Jose, United StatesTaking people
- South DartmouthSouth Dartmouth, United StatesNo longer taking part
- Westlake Brain HealthWestlake, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07101094
- Record updated
- 30 September 2026
- Original description
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapyRead full original descriptionShow less
Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Inclusion: Aged ≥18 years at index date; Have a confirmed diagnosis of schizophrenia before index date; Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy; Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines; Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish); English or Spanish speaking.
Exclusion: Evidence of use of XT prior to time of eligibility screening; Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.